Universe Pharmaceuticals closes $10.75M Best Praise acquisition, issuing 4.38M shares
UPC sits 94% above its 52-week low of $2.
Summary
Universe Pharmaceuticals completed its acquisition of Best Praise International, issuing 4.38 million shares as consideration. The deal adds five patents but dilutes existing shareholders substantially.
Key Events · M&A and Partnerships · UPC
-
Acquisition Closed
Completed purchase of Best Praise International on June 30, 2026, gaining five patents in age-related diseases, neurodegeneration, cognitive disorders, and cardiovascular applications.
-
Share Consideration Issued
Issued all 4,376,552 Class A ordinary shares as consideration, increasing Class A shares outstanding to 5,008,313—dilution of approximately 87% relative to prior Class A count.
-
Resale Registration Rights
Seller granted resale registration rights for the consideration shares, subject to SEC and Nasdaq rules, potentially enabling future sales.
-
Post-Transaction Share Structure
After issuance, total outstanding shares: 5,008,313 Class A and 16,077 Class B ordinary shares.
Analysis · UPC · Life Sciences
The acquisition of Best Praise International closed on June 30, 2026, with Universe Pharmaceuticals issuing all 4,376,552 consideration shares. This adds five pharmaceutical patents in age-related and neurodegenerative diseases to the company's portfolio. The share issuance significantly dilutes existing holders—post-closing, Class A shares outstanding jump to 5,008,313, meaning the newly issued shares represent roughly 87% of the prior Class A count. The deal was paid entirely in stock, preserving cash but amplifying dilution. The filing also confirms resale registration rights for the seller, creating potential future selling pressure.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UPC was trading at $3.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $2.00 to $17.96. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.